VPC
ACHL

Vestal Point Capital’s Achilles Therapeutics ACHL Stock Holding History

Vestal Point Capital’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,500,000
Closed -$1.71M – 86
2024
Q4 		$1.71M Hold
1,500,000
– – 0.1% 68
2024
Q3 		$1.53M Hold
1,500,000
– – 0.12% 65
2024
Q2 		$1.22M Hold
1,500,000
– – 0.09% 57
2024
Q1 		$1.88M Buy
1,500,000
+1,391,917
+1,288% +$1.5M 0.16% 54
2023
Q4 		$96.1K Buy
+108,083
New +$92.7K 0.01% 48

Other funds holding ACHL

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Vestal Point Capital's ACHL Position: Q1 2025 in Review

Vestal Point Capital sold out of Achilles Therapeutics (ACHL) in Q1 2025, closing a stake of 1,500,000 shares — an estimated $1.71M sold.

Vestal Point Capital first reported a position in ACHL in Q4 2023 and held it in 5 quarters. The position peaked at $1.88M in Q1 2024. 6 funds tracked by Wall St. Rank hold ACHL as of Q1 2025.

  • Vestal Point Capital reported no remaining Achilles Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Vestal Point Capital sold 1,500,000 Achilles Therapeutics shares in Q1 2025, an estimated $1.71M.
  • Vestal Point Capital first reported a position in Achilles Therapeutics in Q4 2023 and held it in 5 quarters.
  • Vestal Point Capital's Achilles Therapeutics position peaked at $1.88M in Q1 2024.
  • 6 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2025.

Based on Vestal Point Capital's 13F filing for Q1 2025, filed 15 May 2025.